Plain-English translation of NCT06082063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a multi-medication approach to prevent heart disease in people with type 1 diabetes who are at high risk. Depending on your individual health profile, you may receive , , , or aspirin—along with more aggressive targets for blood pressure and cholesterol control. The goal is to see if this intensive, multi-pronged approach reduces heart attacks, hospitalizations for heart failure, kidney damage, and death better than standard care.
People with type 1 diabetes face a much higher risk of heart disease and kidney failure, even when their blood sugar is well controlled. Current treatment focuses mainly on glucose levels, but this trial asks whether targeting multiple risk factors at the same time—with newer, more powerful medications—can save lives and prevent serious complications.
You likely qualify if…
You likely don't qualify if…
Your clinic will be randomly assigned to either the standard care group or the intensive treatment group. If assigned to intensive treatment, you will take one or more of the new medications plus aspirin, with stricter goals for blood pressure and cholesterol. All participants will have regular clinic visits to check your health, adjust medications as needed, and monitor for heart, kidney, and blood sugar complications. The study will track your outcomes over time to see whether the intensive approach prevents serious events better than usual care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Denmark